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serum phosphorus seems to be the most important vari-
able in determining the observed difference in calcium-
phosphorus product between the treatment groups.
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Using the right MDRD
equation
To the Editor: Estimating the prevalence of renal in-
sufficiency in any patient population is of course a crucial
issue. The earlier renal insufficiency is diagnosed, the best
care is to be provided to the patient, especially in terms
of slackening the progression of renal failure and adjust-
ing drugs dosage when required. In their article, Garg
et al [1] mentioned that they estimated the renal func-
tion of their patients using the Cockcroft-Gault and the
Modification of Diet in Renal Disease Study (MDRD)
formulas. They thus cited Cockcroft and Gault [2] and
Levey et al [3] works in references. The authors fur-
ther detailed the formulas they used in the Appendix of
their article. It is important to remember that Levey et
al tested in their work seven different formulas for es-
timating glomerular filtration rate. They concluded that
among those equations, only one (equation 7) gave sat-
isfactory results. This seventh equation is the one that
should be used in other works when renal function is to
be estimated with the MDRD equation. Unfortunately,
the formula called MDRD formula in Garg’s article is
not the formula validated by Levey et al in the MDRD
article.
MDRD equation for estimating glomerular filtration
rate (GFR):
GFR(mL/min/1.73m2) = 170 × [PCR]−0.999
× [Age]−0.176 × [SUN]−0.170
× [Alb]+0.318
× 0.762 if patient is female
× 1.180 if patient is black
with PCR = serum creatinine concentration (mg/dL), Age
= age of the patient (years), SUN = serum urea nitrogen
(mg/dL), and Alb = serum albumin concentration (g/dL).
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We thank Launay-Vacher et al for their comment. Esti-
mating glomerular filtration rate (GFR) in nursing home
elderly is critical for drug dosing and end of life care,
which may include dialysis. As we highlight in our pa-
per, there are limitations to the use of both Cockcroft-
Gault and Modification of Diet in Renal Disease Study
(MDRD) formulas. The best methods of estimating GFR
for patient care in this population remain to be clarified.
The abbreviated MDRD formula was used in our re-
search study [1]. For transparency of reporting we in-
cluded the formula in the Appendix. The abbreviated
MDRD equation is used throughout Kidney Disease
Outcomes Quality Initiative (K/DOQI) clinical practice
guidelines [2], facilitating comparisons with our results.
Levey et al suggest both MDRD equation 7 and the
abbreviated MDRD formula correlate well with 125I-
iothalamate GFR in middle-aged adults with kidney dis-
ease (R2 = 0.90 and 0.89, respectively) [1]. Finally, the
predictive validity of the abbreviated MDRD formula
has been established—low GFR was a stronsg predictor
of death and end-stage renal disease in a sample of 27,998
adults followed for 5 years [3]. Thus, we strongly dis-
agree with Launay-Vacher et al’s assertion that MDRD
equation 7 was the only valid formula to be used in our
analyses.
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Pathophysiology of
ANCA-associated vasculitis:
Are ANCA really pathogenic?
A note of caution
To the Editor: In their recent article, Heeringa and
Cohen Tervaert summarized the evidences for the widely
accepted conception, that antineutrophil-cytoplasmic au-
toauntibodies (ANCA), by activating neutrophils, are the
“major players” in the pathogenesis of small vessel vas-
culitis [1]. We feel a note of caution is appropriate.
First, there is no evidence for binding of ANCA to
polymorphonuclear neutrophils (PMN) (or monocytes)
in vivo: in patients with high ANCA titer, immunoglob-
ulin G (IgG) deposits cannot be detected on PMN, al-
though the target antigen, for example, PR3, could be
detected by use of a heterologous antibody (e.g., in the
histologic study described in [2], or the the ex vivo anal-
ysis of peripheral blood PMN described in [3]).
Second, to the best of our knowledge, the experiments
using ANCA for activation of PMN in vitro were per-
fomed with purified IgG, or with heterologous antibod-
ies, respectively. According to our experience, the affinity
of the ANCA for PMN is far too low for binding in the
presence of other plasma proteins. With purified IgG, the
low affinity binding can be overcome by high input of pu-
rified protein. Thus, stimulation of PMN by ANCA may
not occur under in vivo conditions.
Third, in the studies with experimental animals (as
reported, e.g., in [4]), the antibodies generated against
myeloperoxidase (MPO) are not true autoantibodies, be-
cause animals deficient for MPO were used for immu-
nization. These animals are not tolerant to MPO, and
consequently, lymphocytes with high reactivity towards
“self-MPO” will not be eliminated, leading to the gener-
ation of antibodies with high affinity binding. In contrast,
when self-tolerance is operative (as it is in humans), anti-
bodies with low affinity binding are produced, which will
greatly differ with regard to their interaction with poten-
tial target antigens.
While these argument do not necessarily rule out a role
of ANCA in vasculitis—or of the PMN—they challenge
the current model of ANCA-mediated PMN activation
as a major pathogenic factor.
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We would like to respond to the issues raised con-
cerning our recent paper on the pathogenic potential of
ANCA [1]. First, it is stated that there is no evidence for
binding of ANCA to PMN in vivo. In our view, such stud-
ies would be technically very challenging, and multiple
reasons can be given for a negative outcome of such stud-
ies. Among others, these include the rapid clearing from
the circulation of ANCA-coated PMNs and the possibil-
ity of internalization of the membrane-bound MPO/anti-
MPO or Pr3/anti-Pr3 immune complexes.
The second issue concerns the affinity of ANCA for
their target antigens on the PMN surface being too low
to induce PMN activation in vivo. Although studies have
been performed using ANCA containing whole sera [2],
purification of the autoantibodies is common practice to
avoid confounding PMN activating mediators (e.g., cy-
tokines) that could be present in whole sera. Although it is
difficult to directly translate the results from such in vitro
studies to the in vivo situation in patients, they clearly
indicate that ANCA, under the right circumstances, can
activate PMN. In our view, this probably does not occur
systemically but locally when PMNs have bound to en-
dothelial cells. Other factors (infection?) are needed ini-
tially to create a proinflammatory environment, resulting
in PMN priming and adherence to activated endothelium.
